Saturday, October 14, 2023
TearClear reports positive topline results from CLEAR Phase 3 study for the treatment of glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%); Haag-Streit to host variety of educational webinars; and more.
Thursday, December 22, 2022
IVERIC bio submits to the FDA the third and final part of its NDA for rolling review of avacincaptad pegol; First patient enrolled in Viridian Therapeutics' THRIVE Phase 3 trial in patients with TED; and more.
Friday, December 16, 2022
Thea Pharma announces FDA approval for the NDA of IYUZEH (latanoprost ophthalmic solution) 0.005% for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension; Amgen announces its acquiring Horizon Therapeutics; and more.
Friday, December 9, 2022
Ocuphire Pharma Submits NDA to the FDA for phentolamine ophthalmic solution 0.75% (Nyxol) for the reversal of pharmacologically induced mydriasis; Lumibird Medical launches next generation YAG/SLT laser, the Tango Reflex Neo, by Ellex for anterior-segment YAG and glaucoma indications; and more.
Friday, December 2, 2022
Aldeyra submits NDA to the FDA for topical ocular reproxalap, an investigational new drug IND candidate for the treatment of signs and symptoms of DED; Kala submits an IND to the FDA for KPI-012 for the treatment of persistent corneal epithelial defect; and more.
Wednesday, November 23, 2022
Alcon completes acquisition of Aerie Pharmaceuticals; FDA accepts Apellis Pharmaceuticals’ unsolicited major amendment to the NDA for intravitreal pegcetacoplan for the treatment of GA secondary to AMD; and more.
Friday, November 18, 2022
FDA grants Breakthrough Therapy designation for IVERIC bio's avacincaptad pegol (ACP, also known as Zimura) for the treatment of GA secondary to AMD; AEYE Health receives 510(k) clearance from the FDA to market AEYE-DS for diabetic retinopathy; and more.
Friday, November 11, 2022
FDA accepts Tarsus' NDA for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis; IVERIC bio submits first part of NDA for rolling review to the FDA for avacincaptad pegol (ACP, Zimura); and more.
Friday, November 4, 2022
Outlook Therapeutics announces acceptance of biologics license application by FDA for ONS-5010 as a treatment for wet AMD; Nicox reports achieving primary objective in Mont Blanc, the first Phase 3 glaucoma trial for NCX 470; and more.
Friday, October 21, 2022
Eyenovia reports positive results from VISION-2 Phase 3 study of MicroLine as potential topical, on-demand treatment for presbyopia; Lenstec rebrands new multifocal IOL, the SBL-3, to ClearView 3; and more.
Friday, October 7, 2022
FDA clears NovaSight's CureSight digital therapy device for amblyopia; Alimera Sciences' PALADIN Phase 4 study confirms ILUVIEN patients' reduced need for multiple treatments; and more.
Friday, September 30, 2022
Johnson & Johnson Vision announces availability of presbyopia-correcting IOL powered by InteliLight technology, TECNIS Symfony OptiBlue IOL; Alcon introduces Clareon Toric IOL with STABLEFORCE Haptics technology, and more.
Friday, September 23, 2022
Coherus announces commercial availability, beginning Oct. 3, 2022, of CIMERLI; Prevent Blindness declares Sept. 26-Oct. 2, 2022, second annual Inflammatory Eye Disease Awareness Week; and more.
Friday, September 16, 2022
Glaukos announces positive topline outcomes for both Phase 3 pivotal trials of iDose TR; Regeneron announces primary endpoints were met in two pivotal trials investigating aflibercept 8 mg; and more.
Friday, September 9, 2022
Bausch + Lomb and Novaliq announce FDA filing acceptance for NOV03; IVERIC bio reports positive topline results from GATHER2 second Phase 3 clinical trial of Zimura; and more.
Friday, September 2, 2022
Outlook Therapeutics re-submits its biologics license application to the FDA for ONS-5010; Vyluma completes last patient visit for primary analysis of Phase 3 CHAMP study.
Thursday, September 1, 2022
This acquisition by BroadcastMed will allow PentaVision to continue as the premier content provider in eye care.
Monday, January 1, 0001
Outlook Therapeutics announces acceptance of biologics license application by FDA for ONS-5010 as a treatment for wet AMD; Nicox reports achieving primary objective in Mont Blanc, the first Phase 3 glaucoma trial for NCX 470; and more.
